• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Clinical value of calcium antagonists in treatment of cardiovascular disorders.

作者信息

Krikler D M, Rowland E

出版信息

J Am Coll Cardiol. 1983 Jan;1(1):355-64. doi: 10.1016/s0735-1097(83)80035-7.

DOI:10.1016/s0735-1097(83)80035-7
PMID:6131086
Abstract

All calcium antagonists have the ability to decrease the symptoms and signs in some patients with ischemic heart disease and help lower the blood pressure in hypertensive persons, but in clinical doses nifedipine does not exhibit antiarrhythmic properties, although these are an important part of the action of verapamil, diltiazem and some substances with a similar chemical structure. In certain disorders beta-adrenergic blocking drugs are useful adjuncts, and under some circumstances, particularly variant angina and supraventricular arrhythmias, specific calcium antagonists are the drugs of choice. More data are needed to define the role of calcium antagonists during cardiopulmonary bypass, in the protection of the ischemic myocardium, in the management of hypertrophic cardiomyopathy and in specific cases of primary pulmonary hypertension. When used with an appropriate sense of perspective and careful observation, calcium antagonists provide useful additional means of helping selected patients suffering from particular cardiovascular diseases.

摘要

相似文献

1
Clinical value of calcium antagonists in treatment of cardiovascular disorders.
J Am Coll Cardiol. 1983 Jan;1(1):355-64. doi: 10.1016/s0735-1097(83)80035-7.
2
Calcium antagonists and cardiovascular disorders.钙拮抗剂与心血管疾病
Ann Cardiol Angeiol (Paris). 1984 Dec;33(8):513-8.
3
Welcome--the calcium channel blockers.欢迎——钙通道阻滞剂。
Chest. 1981 Dec;80(6):657-9. doi: 10.1378/chest.80.6.657.
4
Calcium channel blocking drugs. Part II: Clinical applications.钙通道阻滞剂。第二部分:临床应用。
Compr Ther. 1985 Oct;11(10):67-71.
5
Calcium ions, drug action and the heart--with special reference to calcium antagonist drugs.钙离子、药物作用与心脏——特别提及钙拮抗剂药物
Pharmacol Ther. 1984;25(3):271-95. doi: 10.1016/0163-7258(84)90002-0.
6
Understanding the calcium channel blockers.了解钙通道阻滞剂。
Heart Lung. 1984 Sep;13(5):563-73.
7
Clinical applications of slow channel blocking compounds.慢通道阻断化合物的临床应用。
Pharmacol Ther. 1983;23(1):1-43. doi: 10.1016/0163-7258(83)90025-6.
8
Calcium channel blockers for cardiovascular disorders.用于心血管疾病的钙通道阻滞剂。
Arch Intern Med. 1982 Mar;142(3):452-5.
9
Calcium antagonists in patients with cardiovascular disease. Current perspectives.心血管疾病患者中的钙拮抗剂。当前观点。
Medicine (Baltimore). 1985 Jan;64(1):61-73. doi: 10.1097/00005792-198501000-00005.
10
Calcium channel blocking agents. Council on scientific affairs.钙通道阻滞剂。科学事务委员会。
JAMA. 1983 Nov 11;250(18):2522-4.

引用本文的文献

1
Management of pregnant patients with pulmonary arterial hypertension.肺动脉高压孕妇的管理
Front Cardiovasc Med. 2022 Nov 10;9:1029057. doi: 10.3389/fcvm.2022.1029057. eCollection 2022.
2
Tiapamil, a new calcium channel blocking agent for the treatment of effort induced chronic stable angina pectoris.
Eur J Clin Pharmacol. 1986;30(4):387-92. doi: 10.1007/BF00607949.
3
PY 108-068--acute effects of a single oral dose in chronic stable angina.
Eur J Clin Pharmacol. 1986;30(2):167-70. doi: 10.1007/BF00614296.
4
A comparison of nine calcium ion antagonists and propranolol: exercise tolerance, heart rate and ST-segment changes in patients with chronic stable angina pectoris.
Eur J Clin Pharmacol. 1987;32(6):539-48. doi: 10.1007/BF02455985.
5
Comparative effects of prolonged therapy with four calcium ion antagonists (diltiazem, nicardipine, tiapamil and verapamil) in patients with chronic stable angina pectoris.
Cardiovasc Drugs Ther. 1987;1(1):81-7. doi: 10.1007/BF02125837.